What is Zacks Research's Forecast for NKTR FY2024 Earnings?

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities research analysts at Zacks Research increased their FY2024 EPS estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Monday, January 6th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings of ($0.76) per share for the year, up from their previous estimate of ($0.80). The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.71) per share. Zacks Research also issued estimates for Nektar Therapeutics' Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.87) EPS, Q1 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS and FY2026 earnings at ($0.89) EPS.

A number of other research firms also recently issued reports on NKTR. B. Riley assumed coverage on Nektar Therapeutics in a research report on Wednesday. They set a "buy" rating and a $4.00 price target for the company. Piper Sandler started coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They set an "overweight" rating and a $7.00 price target on the stock. HC Wainwright assumed coverage on Nektar Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $6.50 target price for the company. Finally, BTIG Research reaffirmed a "buy" rating and set a $4.00 price target on shares of Nektar Therapeutics in a research report on Monday, September 30th. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $4.08.

Nektar Therapeutics Price Performance

NKTR stock traded down $0.05 on Thursday, hitting $1.14. 1,843,848 shares of the company were exchanged, compared to its average volume of 2,146,048. The stock has a market capitalization of $210.28 million, a price-to-earnings ratio of -1.36 and a beta of 0.59. The business's fifty day moving average is $1.09 and its two-hundred day moving average is $1.21. Nektar Therapeutics has a twelve month low of $0.48 and a twelve month high of $1.93.

Institutional Investors Weigh In On Nektar Therapeutics

Large investors have recently made changes to their positions in the company. Victory Capital Management Inc. purchased a new stake in shares of Nektar Therapeutics during the 2nd quarter worth about $29,000. Valence8 US LP acquired a new stake in shares of Nektar Therapeutics in the third quarter valued at about $34,000. Intech Investment Management LLC acquired a new stake in shares of Nektar Therapeutics in the third quarter worth $41,000. XTX Topco Ltd acquired a new stake in Nektar Therapeutics in the 3rd quarter worth $46,000. Finally, Erste Asset Management GmbH bought a new position in Nektar Therapeutics during the third quarter valued at about $61,000. Institutional investors and hedge funds own 75.88% of the company's stock.

Insider Activity

In related news, insider Jonathan Zalevsky sold 51,115 shares of the firm's stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the sale, the insider now directly owns 326,904 shares in the company, valued at approximately $307,289.76. This trade represents a 13.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Howard W. Robin sold 46,995 shares of the business's stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $1.01, for a total value of $47,464.95. Following the sale, the chief executive officer now directly owns 1,195,710 shares in the company, valued at $1,207,667.10. This trade represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 155,575 shares of company stock valued at $149,878. 3.71% of the stock is currently owned by company insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.